MX362533B - Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa. - Google Patents

Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.

Info

Publication number
MX362533B
MX362533B MX2014012321A MX2014012321A MX362533B MX 362533 B MX362533 B MX 362533B MX 2014012321 A MX2014012321 A MX 2014012321A MX 2014012321 A MX2014012321 A MX 2014012321A MX 362533 B MX362533 B MX 362533B
Authority
MX
Mexico
Prior art keywords
combination
11beta
somatostatin
analogs
hydroxylase inhibitors
Prior art date
Application number
MX2014012321A
Other languages
English (en)
Other versions
MX2014012321A (es
Inventor
Li Li
Hans Gericke Germo
Anton Schmid Herbert
Roberto Maldonado Lutomirsky Mario
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2014012321A publication Critical patent/MX2014012321A/es
Publication of MX362533B publication Critical patent/MX362533B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Abstract

La presente invención se refiere a una combinación que comprende: (a) un análogo de somatostatina, y (b) un inhibidor de 11-beta-hidroxilasa; cada uno en forma libre o en la forma de una sal farmacéuticamente aceptable de los mismos; al uso de esta combinación para la preparación de un medicamento para el tratamiento de las enfermedades asociadas con un aumento en los niveles de hormonas de estrés; a un paquete o producto comercial que comprende dicha combinación; y a un método de tratamiento de un animal de sangre caliente, en especial de un ser humano.
MX2014012321A 2012-04-12 2013-04-10 Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa. MX362533B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261623117P 2012-04-12 2012-04-12
PCT/EP2013/057515 WO2013153129A1 (en) 2012-04-12 2013-04-10 Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Publications (2)

Publication Number Publication Date
MX2014012321A MX2014012321A (es) 2015-09-24
MX362533B true MX362533B (es) 2019-01-23

Family

ID=48289057

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014012321A MX362533B (es) 2012-04-12 2013-04-10 Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.

Country Status (12)

Country Link
US (1) US9333234B2 (es)
EP (1) EP2836228B1 (es)
JP (1) JP6383352B2 (es)
KR (1) KR102136214B1 (es)
CN (1) CN104321074B (es)
AU (1) AU2013246908B2 (es)
BR (1) BR112014025058B1 (es)
CA (1) CA2869442C (es)
IN (1) IN2014DN09240A (es)
MX (1) MX362533B (es)
RU (1) RU2663455C2 (es)
WO (1) WO2013153129A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS58234B1 (sr) * 2010-01-14 2019-03-29 Novartis Ag Upotreba agensa za modifikovanje hormona adrenalina
EA033685B1 (ru) * 2014-07-07 2019-11-15 Novartis Ag Фармацевтические лекарственные формы
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
WO2017127448A1 (en) 2016-01-19 2017-07-27 Corcept Therapeutics, Inc. Differential diagnosis of ectopic cushing's syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0102839A3 (en) * 1998-07-30 2002-02-28 Sod Conseils Rech Applic Methods of using lanreotide, a somatostatin analogue and pharmaceutical compositions comprising thereof
JP2004531520A (ja) * 2001-04-09 2004-10-14 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド ソマトスタチンアゴニスト
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
WO2011064376A1 (en) * 2009-11-30 2011-06-03 Novartis Ag Imidazole derivatives as aldosterone synthase inhibitors
RS58234B1 (sr) 2010-01-14 2019-03-29 Novartis Ag Upotreba agensa za modifikovanje hormona adrenalina
WO2013131879A1 (en) * 2012-03-07 2013-09-12 Novartis Ag New application for pasireotide

Also Published As

Publication number Publication date
BR112014025058A2 (es) 2017-06-20
RU2663455C2 (ru) 2018-08-06
BR112014025058B1 (pt) 2022-07-12
AU2013246908B2 (en) 2016-06-30
EP2836228B1 (en) 2024-03-20
EP2836228A1 (en) 2015-02-18
AU2013246908A1 (en) 2014-10-23
MX2014012321A (es) 2015-09-24
IN2014DN09240A (es) 2015-07-10
JP2015512923A (ja) 2015-04-30
US9333234B2 (en) 2016-05-10
KR20150004831A (ko) 2015-01-13
CN104321074A (zh) 2015-01-28
KR102136214B1 (ko) 2020-07-22
WO2013153129A1 (en) 2013-10-17
CA2869442A1 (en) 2013-10-17
CN104321074B (zh) 2017-09-08
JP6383352B2 (ja) 2018-08-29
RU2014145351A (ru) 2016-06-10
CA2869442C (en) 2020-09-08
US20150087588A1 (en) 2015-03-26

Similar Documents

Publication Publication Date Title
TN2015000278A1 (en) Autotaxin inhibitors
PH12016501830A1 (en) Inhibitors of c5a for the treatment of viral pneumonia
MX2012012438A (es) Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina.
NZ762034A (en) Human plasma kallikrein inhibitors
PH12014501984A1 (en) Pharmaceutical compositions comprising metformin and a dpp-4 inhibitor or a sglt-2 inhibitor
PH12017500453B1 (en) Spirocyclic inhibitors of cathepsin c
MX2017002816A (es) Derivados de pirazolopiridina y su uso en terapia.
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
PH12017501688A1 (en) Intranasal benzodiazepine pharmaceutical compositions
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
IN2015DN00528A (es)
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2017001461A (es) Terapia de combinacion.
MX2014012321A (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
PH12014502065A1 (en) Vesicular formulations
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2017014776A (es) Combinacion farmaceutica de everolimus con dactolisib.
MX2017001176A (es) Terapia de combinacion.
MX2016006894A (es) Terapia de combinacion que comprende un inhibidor de jak, cdk y pim.
MX2013002503A (es) Combinacion de inhibidores de hdac con farmacos para trombocitopenia.
WO2015200768A3 (en) Pharmacologic treatments of menière's disease
MA39009A (fr) Compositions pharmaceutiques comprenant un agent actif
WO2014155268A3 (en) Fgf-r tyrosine kinase activity inhibitors - use in diseases associated with lack of or reduced snf5 activity

Legal Events

Date Code Title Description
FG Grant or registration